Director of ALTERITY THERAPEUTICS (ATHE) granted 1,000,000 listed options at $1.00
Rhea-AI Filing Summary
ALTERITY THERAPEUTICS LTD director Lawrence Bernard Gozlan, through Montoya Pty Ltd <Buttercup A/C>, received a grant of derivative securities. The award consists of 1,000,000 listed options, each exercisable into one ordinary share at an exercise price of $1.0000 per share.
The options were granted on 15 June 2026 and expire on 15 June 2031. Following this grant, the indirect holdings reported in this listed option position total 1,000,000 options.
Positive
- None.
Negative
- None.
Insights
Director received 1,000,000 long-dated options as equity compensation.
The filing shows 1,000,000 listed options granted to an entity associated with director Lawrence Bernard Gozlan. Each option is exercisable at $1.0000 per share into ordinary shares, expiring on June 15, 2031.
This is a compensation-related acquisition rather than an open-market purchase or sale. The transaction is classified as a grant/award, with indirect ownership reported via Montoya Pty Ltd <Buttercup A/C>. There are no same-day sales or exercises disclosed in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Listed option exp 15 Jun 2031 | 1,000,000 | $0.00 | $0.00 |
Key Figures
Key Terms
Listed option financial
exercise price financial
expiration date financial
indirect ownership financial
underlying security financial
FAQ
What did ALTERITY THERAPEUTICS (ATHE) report in this Form 4 filing?
When do the newly granted ATHE listed options expire?
Is this ATHE Form 4 transaction an open-market buy or a compensation grant?
How is ownership of the ATHE options held for this Form 4 reporting person?
AI-generated analysis. How Rhea-AI works. Not financial advice.